Metabolic Subtyping of Adrenal Tumors: Prospective Multi-Center Cohort Study in Korea
Overview
Authors
Affiliations
Background: Conventional diagnostic approaches for adrenal tumors require multi-step processes, including imaging studies and dynamic hormone tests. Therefore, this study aimed to discriminate adrenal tumors from a single blood sample based on the combination of liquid chromatography-mass spectrometry (LC-MS) and machine learning algorithms in serum profiling of adrenal steroids.
Methods: The LC-MS-based steroid profiling was applied to serum samples obtained from patients with nonfunctioning adenoma (NFA, n=73), Cushing's syndrome (CS, n=30), and primary aldosteronism (PA, n=40) in a prospective multicenter study of adrenal disease. The decision tree (DT), random forest (RF), and extreme gradient boost (XGBoost) were performed to categorize the subtypes of adrenal tumors.
Results: The CS group showed higher serum levels of 11-deoxycortisol than the NFA group, and increased levels of tetrahydrocortisone (THE), 20α-dihydrocortisol, and 6β-hydroxycortisol were found in the PA group. However, the CS group showed lower levels of dehydroepiandrosterone (DHEA) and its sulfate derivative (DHEA-S) than both the NFA and PA groups. Patients with PA expressed higher serum 18-hydroxycortisol and DHEA but lower THE than NFA patients. The balanced accuracies of DT, RF, and XGBoost for classifying each type were 78%, 96%, and 97%, respectively. In receiver operating characteristics (ROC) analysis for CS, XGBoost, and RF showed a significantly greater diagnostic power than the DT. However, in ROC analysis for PA, only RF exhibited better diagnostic performance than DT.
Conclusion: The combination of LC-MS-based steroid profiling with machine learning algorithms could be a promising one-step diagnostic approach for the classification of adrenal tumor subtypes.
Nakano Y, Yokomoto-Umakoshi M, Nakatani K, Umakoshi H, Nakao H, Fujita M J Endocr Soc. 2024; 8(9):bvae140.
PMID: 39145114 PMC: 11322837. DOI: 10.1210/jendso/bvae140.
Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer.
Lakhani A, Kang D, Kang Y, Park J Endocrinol Metab (Seoul). 2023; 38(6):619-630.
PMID: 37989266 PMC: 10764991. DOI: 10.3803/EnM.2023.1814.
Ha J, Park J, Kim K, Kim J, Jung K, Lee J Endocrinol Metab (Seoul). 2023; 38(6):597-618.
PMID: 37828708 PMC: 10765003. DOI: 10.3803/EnM.2023.1789.
Recent Updates on the Management of Adrenal Incidentalomas.
Park S, Kim J Endocrinol Metab (Seoul). 2023; 38(4):373-380.
PMID: 37583083 PMC: 10475962. DOI: 10.3803/EnM.2023.1779.
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.
Mullen N, Curneen J, Donlon P, Prakash P, Bancos I, Gurnell M Endocr Rev. 2023; 45(1):125-170.
PMID: 37556722 PMC: 10765166. DOI: 10.1210/endrev/bnad026.